2016: Operational Progress and Robust Financial Position for Further Growth

2016: Operational Progress and Robust Financial Position for Further Growth

Uncategorized March 7, 2017 at 2:48 PM 0 comments

Cash, cash equivalents and financial instruments* amounted to €230.7m (million euros) as of December 31, 2016 Revenue and other income amounted to €65.7m (€25.1m in 2015), including $15m (€13.8m) milestone payment from Bristol-Myers Squibb related to progress with lirilumab Operating expenses amounted to €58.2m (€35.9m in 2015); increase driven byRead More

Mental Health Specialist Commends UK Grime Star’s Bravery on Depression

Neurology March 7, 2017 at 1:54 PM 0 comments

March 7, 2017 – Following recent news that reveals a quarter of men self-harm in order to cope with depression, UK grime artist Stormzy’s live television discussion on his experiences with depression has been highly praised by a mental health specialist. Stormzy, (Michael Omari),  opened up about his battle withRead More

Pfizer Selects Turner & Townsend for Expansion of Its Clinical Research Unit in Belgium

Uncategorized March 6, 2017 at 2:49 PM 0 comments

Global consultancy Turner & Townsend provides project, cost and commercial management services for two fit outs in Brussels, Belgium First part of the project involved the refurbishment of 578 sq m of office accommodating 60 people and a new subject screening area Turner & Townsend is currently working on aRead More

New Results from Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira® in Treatment of Moderate to Severe Plaque Psoriasis

Dermatology March 6, 2017 at 8:58 AM 0 comments

Additional Phase 3 Study Data Show Significant Efficacy of Guselkumab in Patients Experiencing Inadequate Response to STELARA® in the Treatment of Moderate to Severe Plaque Psoriasis. Orlando, Florida, 3 March, 2017 ― Janssen Research & Development, LLC (Janssen) announced today new findings from two pivotal Phase 3 studies reporting theRead More

Clinical and Preclinical Data on Monalizumab to Be Presented at Aacr Annual Meeting 2017

Uncategorized March 3, 2017 at 8:58 AM 0 comments

Reinforcing safety profile of monalizumab and rationale for broad ability to combine with other anticancer agents. Marseille, France, March 2, 2017 – Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH) today announces that data on monalizumab will be presented at the American Association for Cancer Research (AACR)Read More

Introducing the European Medical Journal 2.1

Introducing the European Medical Journal 2.1

European Medical Journal March 2, 2017 at 8:44 AM 0 comments

United Kingdom, March 2, 2017: A warm welcome to the year’s first issue of the flagship eJournal, the European Medical Journal. Contained within is a collection of peer-reviewed articles plucked from a plethora of therapeutic areas, aiming to facilitate an interdisciplinary transfer of knowledge and to promote a holistic medicalRead More

Positive Results for Relvar® Ellipta® Lung Function Study in Patients with Well-Controlled Asthma

Respiratory February 23, 2017 at 3:19 PM 0 comments

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from a non-inferiority lung function study, which demonstrated that patients with well-controlled asthma were able to switch to the once-daily Relvar® Ellipta® (fluticasone furoate/vilanterol, FF/VI) 100/25, an inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) combination, from the twice-dailyRead More

Philips Reinforces Leadership in Image-Guided Therapy Solutions with Global Launch of next Generation Azurion Platform

Philips Reinforces Leadership in Image-Guided Therapy Solutions with Global Launch of next Generation Azurion Platform

Uncategorized February 23, 2017 at 3:03 PM 0 comments

Developed in collaboration with leading hospitals worldwide, Philips Azurion is an innovative image-guided therapy platform that allows clinicians to easily and confidently perform a wide range of routine and complex procedures, helping them to optimize interventional lab performance and provide superior care Azurion is powered by ConnectOS, Philips’ newly developed operating system toRead More

Janssen Presents Newly-Published Data on the Use of ZYTIGA® (Abiraterone Acetate) Plus Prednisone in the Real-World, Outside the Clinical Trial Setting

Urology February 17, 2017 at 2:56 PM 0 comments

Janssen Presents Newly-Published Data on the Use of ZYTIGA® (Abiraterone Acetate) Plus Prednisone in the Real-World, Outside the Clinical Trial Setting1 Beerse, Belgium, February 17, 2017 – Janssen-Cilag International NV today announced the publication of data revealing radiographic progression-free survival (rPFS) of 16.5 months (95% CI, 13.5–20.0) and treatment durationRead More

New Data Shows Stelara® (Ustekinumab) Maintained Clinical Response and Remission After Two Years of Treatment in Patients with Moderate to Severe Crohn’s Disease

Gastroenterology February 17, 2017 at 2:22 PM 0 comments

Results of the IM-UNITI Study Presented at the 12th Congress of ECCO Barcelona, Spain, February 17, 2017 – Janssen-Cilag International NV (“Janssen”) announced today new two-year data from the ongoing IM-UNITI long-term extension (LTE) study evaluating the efficacy and safety of subcutaneous (SC) STELARA® (ustekinumab) in patients with moderate toRead More